The Treatment Gap in Osteoporosis

Area of Science:

• Bone Metabolism and Endocrinology
• Geriatric Medicine
• Pharmacology

Background:

• Osteoporosis affects millions globally, characterized by low bone density and increased fracture risk.
• Diagnosis relies on bone mineral density measurements.
• Current US prevalence is approximately ten million, with a growing incidence.

Purpose of the Study:

• To review current evidence on osteoporosis treatment efficacy.
• To discuss potential side effects of osteoporosis medications.
• To highlight the benefits of osteoporosis treatment and address the treatment gap.

Main Methods:

• Literature review of recent evidence on osteoporosis diagnostics and therapeutics.
• Summary of efficacy and safety data for various osteoporosis medications.
• Analysis of factors contributing to the osteoporosis treatment gap.

Main Results:

• Established osteoporosis treatments include bisphosphonates, denosumab, raloxifene, and teriparatide, with romosozumab recently added.
• Advances in diagnostics and treatments exist, yet a significant treatment gap persists.
• Concerns about rare side effects (e.g., osteonecrosis of the jaw) and insufficient patient information contribute to undertreatment.

Conclusions:

• Improving patient knowledge of treatment benefits and options can enhance compliance.
• Addressing patient concerns and side effect worries is crucial for reducing the treatment gap.
• Comprehensive understanding of treatment efficacy and risks is vital for managing osteoporosis effectively.